Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis.

PsA comorbid disease epidemiology incidence insurance health claims data psoriasis risk factors

Journal

Rheumatology advances in practice
ISSN: 2514-1775
Titre abrégé: Rheumatol Adv Pract
Pays: England
ID NLM: 101736676

Informations de publication

Date de publication:
2020
Historique:
received: 19 03 2020
revised: 17 06 2020
entrez: 2 11 2020
pubmed: 3 11 2020
medline: 3 11 2020
Statut: epublish

Résumé

Psoriasis is a systemic inflammatory disease often accompanied by comorbidities, including metabolic syndrome, cardiovascular diseases and depression. Up to 41% of psoriasis patients develop psoriatic arthritis (PsA), making it one of the most relevant manifestations. A large health claims data set was analysed to determine the rate of PsA development in psoriasis patients. Furthermore, comorbid disease profiles of psoriasis patients with or without PsA were compared, and potential risk factors for the development of PsA were identified. This was a non-interventional, retrospective analysis of anonymized insurance health claims data using a subset of the Institute of Applied Health Research Berlin (InGef) database. The primary outcome was the prevalence and incidence of diagnosed PsA among psoriasis patients in Germany. Risk factors for the development of PsA in psoriasis patients were determined by conditional logistic regression analysis. The cumulative percentage of patients with existing psoriasis developing concomitant PsA over 4 years was 3.44%, with a mean time to diagnosis of PsA of 1.5 years. Psoriasis patients diagnosed with acute rheumatism (odds ratio: 2.93, 95% CI = 1.76, 4.86; Unspecific arthritic symptoms are likely to precede PsA diagnoses and can develop soon after onset of psoriasis, with accumulating risk over time. There is a high unmet need for early rheumatological assessment of psoriasis patients.

Identifiants

pubmed: 33134811
doi: 10.1093/rap/rkaa033
pii: rkaa033
pmc: PMC7585407
doi:

Types de publication

Journal Article

Langues

eng

Pagination

rkaa033

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Références

Nat Rev Rheumatol. 2011 Sep 13;7(10):588-98
pubmed: 21912431
Ann Rheum Dis. 2013 May;72(5):736-40
pubmed: 22730367
Br J Dermatol. 2009 May;160(5):1040-7
pubmed: 19210498
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
Arch Dermatol Res. 2012 Nov;304(9):719-26
pubmed: 22868902
Ann Rheum Dis. 2011 Dec;70(12):2152-4
pubmed: 21914627
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963
pubmed: 28895202
Arthritis Care Res (Hoboken). 2019 Aug;71(8):1084-1091
pubmed: 30171803
Rheumatol Int. 2018 Nov;38(11):2121-2131
pubmed: 30094685
Br J Dermatol. 2017 Mar;176(3):650-658
pubmed: 27579733
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii18-23; discussion ii24-5
pubmed: 15708928
J Eur Acad Dermatol Venereol. 2010 May;24(5):548-54
pubmed: 19874432
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94
pubmed: 26481193
Rheumatology (Oxford). 2003 Jun;42(6):778-83
pubmed: 12730539
J Dermatolog Treat. 2006;17(5):279-87
pubmed: 17092858
Drugs. 2014 Mar;74(4):423-41
pubmed: 24566842
J Am Acad Dermatol. 2015 Aug;73(2):242-8
pubmed: 26054432
Arthritis Res Ther. 2018 Jul 27;20(1):153
pubmed: 30053825
Arch Dermatol. 2010 Aug;146(8):891-5
pubmed: 20713823
Rheumatology (Oxford). 2012 Mar;51(3):571-6
pubmed: 22157469
Br J Dermatol. 2013 Jun;168(6):1303-10
pubmed: 23374051
Arthritis Care Res (Hoboken). 2011 Apr;63(4):619-22
pubmed: 21452273
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
Gesundheitswesen. 2011 May;73(5):308-13
pubmed: 20544588
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Ann Rheum Dis. 2016 Dec;75(12):2068-2074
pubmed: 26916344
J Rheumatol. 1990 Jun;17(6):809-12
pubmed: 2388203
J Am Acad Dermatol. 2013 Nov;69(5):729-735
pubmed: 23981683
Psoriasis Forum. 2010 Winter;16(4):17-25
pubmed: 25346592
Rambam Maimonides Med J. 2017 Jan 30;8(1):
pubmed: 28178440
BioDrugs. 2013 Aug;27(4):359-73
pubmed: 23580094
Semin Cutan Med Surg. 2005 Mar;24(1):46-51
pubmed: 15900798
J Am Acad Dermatol. 2005 Oct;53(4):573
pubmed: 16198775
Dermatol Clin. 2015 Jan;33(1):41-55
pubmed: 25412782
Z Rheumatol. 2010 Mar;69(2):157-60, 162-3
pubmed: 19455345

Auteurs

Jürgen Rech (J)

Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany.

Michael Sticherling (M)

Hautklinik, Universitätsklinikum Erlangen, Erlangen, Germany.

Daniel Stoessel (D)

Elsevier Health Analytics, Berlin, Germany.

Mona H C Biermann (MHC)

Novartis Pharma GmbH, Nürnberg, Germany.

Benjamin M Häberle (BM)

Novartis Pharma GmbH, Nürnberg, Germany.

Maximilian Reinhardt (M)

Novartis Pharma GmbH, Nürnberg, Germany.

Classifications MeSH